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Background: Artequick is a relatively inexpensive artemisinin (Qing-hao-su; QHS)-based combination therapy (ACT)
that contains QHS and piperaquine (PQ), which has not been widely used because of the decreased concentration
level of QHS after repeated oral administrations for five to seven days as a monotherapy. This study was designed to
evaluate the potential auto-induction metabolism of QHS in healthy Chinese adults after a two-day oral administration
of QHS-PQ. The effect of QHS-PQ on the activity of the CYP2B6 and CYP3A4 was also investigated.
Methods: Fourteen healthy Chinese subjects received two-day oral doses of QHS-PQ (Artequick). A two-drug cocktail
consisting of bupropion and midazolam was used to assess the activities of CYP2B6 and CYP3A, respectively. Plasma
samples were analysed for QHS and its phase I/II metabolites, probe drugs and their metabolites, using a validated
liquid chromatography tandem mass spectrometric (LC-MS) method.
Results: Four major phase I metabolites of QHS (M1-M3 and deoxy-QHS) and two subsequent phase II metabolites
(M4-M5) were detected in human plasma after oral administrations of QHS-PQ. The AUC0-t of the QHS and its phase I
metabolites decreased significantly (P < 0.05) with increased oral clearance (CL/F) after two-day oral doses of QHS-PQ,
whereas its phase II metabolites exhibited higher AUC (P < 0.01). The phase I metabolic capability, calculated by the
AUC0-t ratio of all phase I metabolites to QHS, increased 1.5-fold after the repeated dose (P < 0.01), and the phase II
metabolic capability increased 1.5-fold for M4 and 3.0-fold for M5. The enzyme activity of CYP2B6 and CYP3A4
increased 2.1-fold and 3.2-fold, respectively, after two-day oral doses of QHS-PQ.
Conclusions: The auto-induction of both phase I and phase II metabolism of QHS was present in healthy Chinese
subjects after a recommended two-day oral dose of QHS-PQ. The auto-induction metabolism also existed for phase I
metabolites of QHS. The enzyme activity of CYP2B6 and CYP3A4 was induced after the two-day oral doses of QHS-PQ.
Based on these results, the alternative common three-day regimen for QHS-PQ could probably lead to lower
bioavailability of QHS and higher potential of drug-drug interaction caused by the induction of drug-metabolizing
enzymes.
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Artemisinin (QHS) and its semisynthetic derivatives are
the most potent anti-malarials available for treatment of
falciparum malaria infections. Artemisinin-based com-
bination therapy (ACT) is the recommended treatment
for uncomplicated Plasmodium falciparum malaria by
World Health Organization (WHO). The present forms
of ACT contain artemether (ARM) plus lumefantrine
(Coartem®), artesunate (ARS) plus either amodiaquine,
mefloquine or sulphadoxine-pyrimethamine, and dihy-
droartemisinin (DHA) plus piperaquine (Artekin®). Al-
though new sources of QHS are emerging from chemical
synthesis [1] and engineered microbes [2], QHS is
currently only commercially available from the plant
Artemisia annua (Asteraceae). The production of
semisynthetic derivatives of QHS adds to the manufactu-
ring cost. Artequick® (Artepharm Co Ltd, Guangzhou,
China) is a recently marketed and relatively inexpensive
ACT, which contains QHS instead of its derivatives plus
piperaquine (PQ). The current manufacturer's recom-
mendation for Artequick is a two-day regimen, which
contrasts with the three-day recommended for all ACT
by WHO. The simplified dosing scheme (two-day ther-
apy) of this QHS-PQ combination may increase patient
compliance and consequently the efficacy of the treat-
ment. However, a shorter treatment regimen might not
be effective in some areas and may cause QHS resist-
ance to emerge more quickly. Several previous reports
suggested that a three-day course of QHS-PQ deserves
further evaluation as an alternative treatment for
multidrug-resistant P. falciparum malaria [3,4].
The metabolism of QHS could be of great importance
in determining the clinical efficacy and optimization of
dose regimens of QHS-PQ. QHS underwent extensive
metabolism, and the fraction of QHS excreted unchanged
in human urine has been found less than 1% of an oral ad-
ministration [5]. In rat liver microsomal (RLMs) incu-
bates, four unknown metabolites (MW 282) of QHS were
detected [6]. In another study, 11 phase I metabolites of
QHS were found in human liver microsomal (HLMs) in-
cubates, RLMs and rat plasma [7]. These hydroxylated
and/or deoxyl products will undergo subsequent glucuro-
nidation processes, and 12 phase II metabolites of QHS
were detected in rat bile, urine and plasma. Four metabo-
lites have been isolated from human urine, which include
deoxy-QHS, deoxydihydroartemisinin, 9,10-dihydroxyar-
temisinin and so-called crystal 7 [5]. Based on the meta-
bolic profiles of QHS in vitro and in rats, related phase I
and phase II metabolites could exist for QHS in human,
which has limited data available, especially in human
blood circulation system.
QHS has not been used to a great extent in ACT
because of its low bioavailability and time-dependent
pharmacokinetics, which have been confirmed in healthyvolunteers and infected patients as a several-fold de-
crease in plasma concentration of QHS with a corre-
sponding increase in oral clearance after repeated oral
administrations for five to seven days [3,8-10]. The auto-
induction metabolism has been suggested for this time-
dependency [11-13]. The elimination of QHS is medi-
ated primarily by CYP2B6, with a probable secondary
contribution of CYP3A4 and CYP2A6 [14,15]. QHS ap-
pears to induce several enzymes, including CYP2B6
(mepheytoin N-demethylation) in vivo and bupropion
hydroxylation in vitro [12,13]; CYP3A4 (midazolam hy-
droxylation [13,16]); CYP2C19 (omeprazole as a marker;
[17,18]); CYP2A6 (coumarin hydroxylation [19]); and
glucuronidation (7-hydroxycoumarin glucuronidation [19]).
However, the auto-induction, metabolism-mediated, time-
dependent pharmacokinetics should be less pronounced if
QHS was used in a combination treatment that had therapy
duration shorter than that used in monotherapy. Although
the tolerability, safety, efficacy, and pharmacokinetic prop-
erties of QHS have been investigated, no direct evidence
was available for the increased concentration level of QHS
phase I/II metabolites in blood circulation system after re-
peated administrations of QHS in human. The effect of
QHS-PQ on the activity of the principal CYP450 enzymes
(especially CYP2B6) involved in drug metabolism has not
yet been studied in vivo.
The main objective of the current study was to evalu-
ate the potential auto-induction metabolism of QHS
during a recommended two-day oral administration of a
new ACT (Artequick). The biotransformation of QHS in
Chinese subjects was studied, and the pharmacokinetic
profiles of QHS and its phase I/phase II metabolites
were investigated. The effect of this ACT on the activity




Artequick tablets were provided by Artepharm Co Ltd
(Guangzhou, China). QHS and ARM (as internal stan-
dard) were purchased from Kunming Pharmaceutical Co
(purity >99.0%, Yunnan, China). Deoxyartemisinin
(Deoxy-QHS; Figure 1) was synthesized in laboratory,
and its structure was confirmed by HR-MS, 1H-NMR
and 13C-NMR spectroscopy. Bupropion (BUP), (±)-hy-
droxybupropion (OH-BUP), midazolam (MDZ), α-
hydroxymidazolam (OH-MDZ) and alprazolam were
purchased from Cerilliant Corporation (Round Rock,
TX, USA). All other chemicals used were purchased
from Sigma-Aldrich or Thermo Fisher Scientific.
Instrumentation
All LC-MS experiments were carried out on a Thermo
































































Figure 1 Structures of phase I (Deoxy-QHS, M1-M3) and phase II (M4, M5) metabolites of artemisinin (QHS) detected in human plasma,
and proposed metabolic pathways for QHS.
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http://www.malariajournal.com/content/13/1/214(ThermoFinnigan, Bremen, Germany) equipped with an
electrospray ionization interface. An Accela HPLC sys-
tem (ThermoElectron) was equipped with an autosam-
pler, a vacuum degasser unit and a quaternary pump.
The mass spectrometer employing positive ionization
was calibrated using the manufacturer’s calibration stan-
dards mixture allowing for mass accuracies < 5 ppm in
external calibration mode. The ionization voltage was
4.2 kV and the capillary temperature was set at 300°C.
Nitrogen was used as both the sheath gas (40 units) and
auxiliary gas (10 units). The resolving power was 15,000
for full-scan and 7,500 for the MS2 scans.
For metabolite identification of QHS, the data-dependent
MS2 acquisition was triggered when the Orbitrap detected
the ions of QHS metabolites on the parent ion list or the
most intense ion. The [M + NH4]
+ adduct ions of QHS andits metabolites were dissociated in the high collision-
induced dissociation (HCD) mode using the normalized
collision energy at 35% with an isolation width of 3 Da
and an activation time of 30 ms. The full scan mode
across an m/z range that bracketed QHS and its potential
phase I/II metabolites was used for quantification of QHS
and its metabolites. Extracted ion chromatograms (EICs)
of m/z 283.1540 for QHS and monohydroxylated deoxy-
QHS, m/z 284.1856 for deoxy-QHS, m/z 316.1775 for
monohydroxylated QHS, m/z 332.1704 for dihydroxylated
QHS, m/z 476.2126 for the glucuronide of monohydroxy-
lated deoxy-QHS, m/z 492.2076 for the glucuronide of
monohydroxylated QHS, and m/z 316.2118 for ARM (the
internal standard; IS), with a 5 ppm range centred on the
exact m/z value were generated for quantitation. Chroma-
tographic separation was achieved on a Luna ODS C18
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CA, USA) with a 4.0 × 3.0 mm i d SecurityGuard C18
(5 μm) guard column (Phenomenex, Torrance, CA, USA).
The chromatography was performed at 22°C. The mobile
phase consisted of acetonitrile and 5 mM aqueous ammo-
nium acetate containing 0.1% (v/v) formic acid, delivered
at a flow rate of 0.35 mL/min. The gradient chromato-
graphic conditions were shown in the previous report [7].
The autosampler was set at 4°C.
For quantification of probe drugs (BUP, MDZ) and
their respective metabolites (OH-BUP, OH-MDZ), the
high-resolution full scan mode was used. Extracted ion
chromatograms (EICs) of m/z 326.0855 for MDZ, m/z
342.0804 for OH-MDZ, m/z 240.1150 for BUP, m/z
256.1099 for OH-BUP, and m/z 309.0902 for alprazolam
(IS), with a 5 ppm range centred on the exact m/z value
were generated for quantitation. Chromatographic separ-
ation was achieved on an Agilent Eclipse XDB C18 col-
umn (150 × 4.6 mm i d, 5 μm; Agilent Technologies,
Santa Clara, CA, USA) with a 4.0 × 3.0 mm i d Security-
Guard C18 (5 μm) guard column (Phenomenex, Torrance,
CA, USA). The chromatography was performed at 22°C.
The mobile phase consisted of B (acetonitrile) and A
(0.1% formic acid in water), which increased linearly
from 20% B to 90% B during 7 min before column re-
equilibration at a flow rate of 0.3 mL/min.
Metabolite identification of QHS
1 mL of pooled human plasma (n = 6) or urine samples
were loaded onto pretreated solid-phase extraction car-
tridges (Oasis extraction cartridges, Waters Corp, Milford,
MS, USA). The cartridges were washed with 1 mL of water
and then eluted with 0.5 mL of methanol. The methanol
fractions were dried and reconstituted with 200 μL of ini-
tial mobile phase. Aliquot (20 μL) of the reconstituted so-
lutions were injected onto LC-HR/MS.
Quantification of QHS and its phase I/II metabolites
Plasma samples were subjected to a protein precipitation
extraction process, which was performed on ice. A 100 μL
aliquot of human plasma was mixed with 25 μL of aceto-
nitrile and 200 μL of IS (1 μM of ARM, prepared in aceto-
nitrile). The mixture was mixed and centrifuged at 3,000 g
for 10 min. Aliquots (20 μL) of the solution were injected
onto LC-MS analysis. For calibration preparation, 100 μL
of drug-free plasma was mixed with 25 μL of stock solu-
tion (QHS and deoxy-QHS) and 200 μL of IS. This mix-
ture was treated as above. The calibration graph was
plotted by least-squares linear regression of the peak-area
ratios (QHS or deoxy-QHS to IS) against concentrations
of QHS or deoxy-QHS. Matrix matched calibration
standards were obtained with concentrations of 17.7-
709.2 nM for QHS and 18.8-751.9 nM for deoxy-QHS
in plasma. QC samples were obtained with threeconcentration levels (35.5, 177.3 and 567.4 nM for QHS;
37.6, 188.0 and 601.5 nM for deoxy-QHS) in plasma.
Due to unavailability of reference substances, quantita-
tive data of the other three phase I metabolites (M1-M3)
and two phase II metabolites (M4-M5) were extracted
based on the calibration curve of QHS. In this study, the
pharmacokinetic profile of each metabolite in humans
after a single oral dose of QHS-PQ will be used to com-
pare with that after a repeated oral dose, in order to
evaluate the auto-induction metabolism. In this case, the
response factor for QHS metabolites compared with that
of QHS was not considered. Plasma samples were di-
luted with blank plasma and reanalysed when the con-
centration of QHS metabolites was higher than the
upper limit of quantification of QHS.
Quantification of probe drugs and their metabolites
Plasma samples were subjected to a protein precipitation
extraction process. A 100 μL aliquot of human plasma
was mixed with 25 μL of acetonitrile and 200 μL of IS
(1 μM of alprazolam, prepared in acetonitrile). The mix-
ture was mixed and centrifuged at 3,000 g for 10 min.
Aliquots (20 μL) of the solution were injected onto LC-
MS analysis. For calibration preparation, 100 μL of drug-
free plasma was mixed with 25 μL of stock solution
(BUP, OH-BUP, MDZ and OH-MDZ) and 200 μL of IS.
This mixture was treated as above. The calibration graph
was plotted by least-squares linear regression of the
peak-area ratios (BUP, OH-BUP, MDZ or OH-MDZ to
IS) against concentrations of BUP, OH-BUP, MDZ or
OH-MDZ. Matrix matched calibration standards were
obtained with concentrations of 7.7-307.7 nM for MDZ,
1.5-58.7 nM for OH-MDZ, 4.2-836.8 nM for BUP, and
19.6-3,921.6 nM for OH-BUP in human plasma. QC
samples were obtained with three concentration levels
(15.4, 76.9 and 246.2 nM for MDZ; 2.9, 14.7 and 46.9 nM
for OH-MDZ; 8.4, 83.7 and 669.5 nM for BUP; 39.2,
392.2, 3,137.3 nM for OH-BUP) in plasma. Plasma sam-
ples were diluted with blank plasma and reanalysed when
the concentration of any analyte was higher than the
upper limit of quantification.
Method validation
Two LC-MS methods were developed for quantifica-
tion of QHS metabolites and probe drugs. The method
was evaluated through linearity, intra- and inter-day
precision and accuracy. The accuracy and precision of
the method were assessed by determining QC samples
using six replicated preparations of plasma samples at
three QC concentration levels on three separate days.
The lower limit of quantification (LLOQ) represents
the lowest concentration of the analyte over the linear
range that can be determined with acceptable precision
and accuracy.
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assessed by leaving the QC samples of two different con-
centrations (35.5 and 567.4 nM for QHS; 37.6 and 601.5
nM for deoxy-QHS) on ice for 2 hours. The stability of
QHS samples in autosampler vials was assessed at 4°C
for 12 hours. The stability of probes drugs (BUP, MDZ)
and their metabolites (OH-BUP, OH-MDZ) were also
evaluated.
Drug administration and sample collection
The experiment followed guidelines of the Declaration of
Helsinki for humans, and the experimental protocol was
approved by the Ethics Committee of Shandong Univer-
sity (Jinan, China) and the Institutional Review Board of
Qilu Hospital (Shandong University, China). The clinical
project was performed at Qilu Hospital (Jinan, China).
Fourteen healthy and non-smoking male volunteers (18–
24 years; body mass index of 19–24 kg/m2) were enrolled
in the clinical trial, and written informed consent was pro-
vided prior to enrolment in this study. They were in good
health as assessed by medical history, physical examin-
ation and laboratory analysis (complete blood count, total
bilirubin, direct bilirubin, serum creatinine, blood urea ni-
trogen, alanine aminotransferase, and serum albumin).
The subjects were fasted overnight before drug adminis-
tration and for a further 2 hours after dosing. Water was
freely available during experiments.
Each subject was treated with QHS-PQ tablets (Arte-
quick) according to manufacturer’s recommendation
(125 mg of QHS plus 750 mg of PQ each day for two con-
secutive days). Venous blood samples (2 mL) for determin-
ation of QHS and its metabolites were taken from an
indwelling intravenous catheter at 0, 0.25, 0.75, 1.25, 1.75,
2.5, 3.0, 4.0, 5.0, 6.0, 8.0, 12.0, 24.0, 36.0 (second dose), and
48.0 hours (second dose) after each dose, and collected in
anticoagulant tubes drawn from forearm venous catheters
before and after oral administration of QHS-PQ. Plasma
was separated by centrifugation at 3,000 g for 10 min at
4°C. The plasma was stored at −80°C until analysis.
The probe drugs, including midazolam (15 mg tablet,
Nhwa Pharma Corp, China) and bupropion (75 mg
tablet, Venturepharm Pharmaceutical Co Ltd, Hainan,
China) were given orally two weeks before (day −14) ad-
ministration of QHS-PQ. The probe drug cocktail was
repeated 1 hour after intake of the second oral dose of
QHS-PQ (day 2). Venous blood samples (2 mL) for ana-
lysis of probe drugs and their metabolites were taken
from an indwelling intravenous catheter at 0, 0.25, 0.75,
1.5, 2.0, 3.0, 4.0, 5.0, 7.0, 11.0, 24.0, 36.0, and 48.0 hours.
Data processing
The peak plasma concentration (Cmax) and time-to-peak
concentration (Tmax) were obtained from experimental
observations. The other pharmacokinetic parameterswere analysed by non-compartmental model using the
program TOPFIT (version 2.0; Thomae GmbH,
Germany). The area under the plasma concentration-
time curve (AUCo-t) was calculated using the linear trap-
ezoidal rule to approximately the last point. The mean
residence time (MRT) was obtained by dividing the area
under the first moment-time curve (AUMC0-t) by the
area under the curve (AUC0-t). Total oral body clearance
(CL/F) was calculated as dose/AUC0-t. The inter-
individual variability of pharmacokinetic parameters of
QHS was calculated by the difference between individual
values and mean values. The metabolic capability leading
to phase I metabolites of QHS was calculated by the
AUC0-t ratio (AUCphase I metabolite/AUCQHS) of phase I
metabolites to the parent drug QHS, and the metabolic
capability to form phase II metabolites of QHS was eval-
uated by the AUC0-t ratio (AUCphase II metabolite/AUCphase
I metabolite) of phase II metabolites to their respective hy-
droxylated metabolites. Induction of phase I metabolism
by QHS was assessed by comparison of the AUCo-∝ ratio
of all phase I metabolites to the parent drug QHS be-
tween one-day and two-day oral doses of QHS-PQ. In-
duction of phase II metabolism by QHS was evaluated
by comparison of the AUCo-t ratio of phase II metabo-
lites to their respective hydroxylated metabolites be-
tween two doses. The enzyme activity of CYP2B6 was
calculated by the AUCo-∝ ratio of OH-BUP to BUP, and
the CYP3A4 activity was determined by the AUCo-∝ ratio
of OH-MDZ to MDZ.
Results were expressed as mean ± SD. The two-tailed
t-test was used for paired comparison of the pharmaco-
kinetic parameters between the single dose and multiple
doses after logarithmic transformation. Geometric mean
ratios with 90% confidence intervals (CIs) were calcu-
lated after log transformation of within-subject data. The
comparison of Tmax for the different treatment groups
was performed using the Wilcoxon signed-rank test.
The acceptable level of significance was established at
P < 0.05 or P < 0.01. A greater than 1.2-fold increase in
AUC/dose or CYP activity, relative to the control, was
defined to be induction.
Results
Metabolite identification of QHS
Human plasma and urine samples were analysed by
liquid chromatography-high resolution mass spec-
trometry (LC-HRMS), as illustrated in selected ion
chromatograms of QHS, its four major phase I metab-
olites and two major phase II metabolites in human
plasma as a representative (Figure 2). Based on the ac-
curate MS and MS/MS spectra, six major metabolites
in human plasma were proposed to be monohydroxy-
lated deoxy-QHS (M1), deoxy-QHS, monohydroxy-
lated QHS (M2), dihydroxylated QHS (M3), the
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and the glucuronide of monohydroxylated QHS (M5),
respectively. Their proposed structures are shown in
Figure 1. Five more phase I metabolites were detected
in human urine, including three monohydroxylated
deoxy-QHS and two monohydroxylated QHS (not
shown). The identification of phase I and phase II me-
tabolites of QHS in vitro and in rats using LTQ/Orbi-
trap has been shown in detail in a previous study [7].
In the present study, the pharmacokinetics of QHS and
its six major metabolites (M1-M5, and deoxy-QHS) in




















































































Figure 2 Representative full-scan chromatograms of (A) a blank huma
plasma sample spiked with artemisinin (QHS; 17.7 nM), deoxyartemis
plasma sample at 1.25 h after a single oral dose of QHS (1.8 mg/kg).
deoxyartemisinin (deoxy-QHS; m/z 284.1856); III: monohydroxylated artemis
the glucuronide of monohydroxylated deoxy-QHS M5 (m/z 476.2126); VI: th
(ARM, m/z 316.2118).LC-MS method for determination of QHS and its
metabolites
Under optimized HPLC conditions, QHS and its phase
I/II metabolites were eluted within 30 min (Figure 2).
Blank human plasma from six lots showed no significant
interfering peaks at the retention times of each analyte
(Figure 2A). The LC separation was improved allowing
the separation of QHS metabolites from their minor
diastereomers.
The calibration curves of QHS and deoxy-QHS were
linear over the concentration range of 17.7-709.2 nM and

















































n plasma sample spiked with IS (ARM, 1 μM); (B) a blank human
inin (Deoxy-QHS; 18.8 nM), and IS (ARM, 1 μM); and (C) a human
I: QHS and monohydroxylated deoxyartemisinin (m/z 283.1540); II:
inin (m/z 316.1775); IV: dihydroxylated artemisinin (m/z 332.1704) V:
e glucuronide of monohydroxylated QHS (m/z 492.2076); VII: IS
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values when evaluated by weighted (1/x2) least-squares
linear regression. The LLOQ of QHS and deoxy-QHS
in human plasma were established at 17.7 and 18.8
nM, respectively. The precision and accuracy of this
method indicate that all coefficients of variation at
each concentration level were below 15%. There was
no significant difference (< 15%) between the responses
of standards at time zero and after storage of plasma
on ice for at least 2 hours in terms of %CV for QHS
and deoxy-QHS, indicating that QHS and deoxy-QHS
were stable under this condition. Processed samples
were stable for at least 12 hours in the autosampler
tray (4°C).
Pharmacokinetics of QHS and its phase I metabolites
The mean plasma concentration-time profiles of QHS
and its phase I metabolites (M1-M3, deoxy-QHS) after
oral dosing of QHS are shown in Figure 3, and the phar-
macokinetic parameters are given in Table 1.
Healthy subjects in this study received a recommended
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Figure 3 Mean (+SD) plasma concentration-time profiles of artemisinin
monohydroxylated deoxy-QHS: M1; monohydroxylated QHS: M2; dihyd
consecutive days of oral doses of QHS (1.8 mg/kg).QHS was rapidly eliminated, with a high mean CL/F of
9.8 L/h/kg and a short mean MRT of 3.2 hours. The dose-
normalized AUC value of QHS was 0.14 ± 0.08 h⋅kg/L
after a single oral dose of QHS. There was also a large
inter-individual variability in QHS pharmacokinetic pa-
rameters, with a %CV of 43.5% (6.9-122.7%) for AUC0-t.
The time-dependent pharmacokinetics existed for QHS,
and the second oral dose of QHS-PQ resulted in a 35.2%
decrease in AUC0-t compared with the first dose. The cor-
responding CL/F value significantly increased 1.7-fold
(90% CI, 1.5-1.9). The Cmax, Tmax and MRT of QHS did
not change (P > 0.05) after repeated drug dosing.
The AUC0-t of the metabolite deoxy-QHS decreased sig-
nificantly (P < 0.01) by 34.7% (20.3-71.8%) in 13 out of 14
subjects with increased CL/F values (1.7-fold), after mul-
tiple oral doses of QHS. The other pharmacokinetic param-
eters (Tmax and MRT) did not change (P > 0.05). The
metabolic capability, calculated by AUCdeoxy-QHS/AUCQHS,
increased 1.6-fold in six subjects after the second dose but
decreased by 41.6% in four subjects (Figure 4).
The metabolite M1, monohydroxylated deoxy-QHS,
was present in relatively high level (mean Cmax of24 36 48
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(QHS) and its phase I metabolites (deoxyartemisinin: Deoxy-QHS;
roxylated QHS: M3) in healthy Chinese (n = 14 each) following two
Table 1 The main pharmacokinetic parameters of artemisinin (QHS) and its phase I/II metabolites (deoxy-QHS,
monohydroxylated deoxy-QHS, monohydroxylated QHS, dihydroxylated QHS, the glucuronide of monohydroxylated
deoxy-QHS, and the glucuronide of monohydroxylated QHS) after one-day and two-day oral administrations of
QHS-PQ (1.8 mg/kg of QHS plus 10.6 mg/kg piperaquine) to 14 healthy Chinese subjects (mean ± sd)
AUC0-t/dose (h⋅kg⋅L
−1) Cmax (nmol⋅L
−1) Tmax (h) MRT (h) CL/F (L/h/kg) AUCM/AUCQHS
1-day QHS 0.14 ± 0.08** 304.3 ± 191.7 1.8 (0.75, 3.0) 3.2 ± 0.9 9.81 ± 8.25** N.A.
DeoxyQHS 0.09 ± 0.05** 71.0 ± 46.1* 2.2 (1.25, 4.0) 7.1 ± 0.6 14.71 ± 8.41** 0.67 ± 0.25
M1 3.72 ± 1.59** 1527.4 ± 721.7 7.0 (3.0, 12.0) 11.6 ± 0.7** 0.36 ± 0.27** 28.80 ± 11.31**
M2 1.66 ± 0.83** 2378.5 ± 1135.6** 2.1 (1.25, 3.0) 4.0 ± 0.6 0.80 ± 0.52** 12.61 ± 4.56
M3 0.49 ± 0.30* 451.6 ± 299.2 3.3 (1.25, 6.0) 5.7 ± 1.2 7.55 ± 15.62* 3.80 ± 2.90
M4 0.02 ± 0.01** 22.8 ± 17.1** 1.9 (0.75, 3.0) 4.4 ± 2.0 135.13 ± 141.70** 0.007 ± 0.01**†
M5 0.02 ± 0.01** 58.7 ± 37.7** 1.7 (0.75, 3.0) 2.4 ± 0.8 82.54 ± 66.47** 0.02 ± 0.02**‡
2-day QHS 0.09 ± 0.05** 221.4 ± 117.9 1.4 (0.75, 1.75) 2.9 ± 0.9 16.60 ± 14.79** N.A.
DeoxyQHS 0.06 ± 0.04** 55.6 ± 33.3* 2.3 (1.25. 5.0) 6.2 ± 1.5 24.71 ± 20.75** 0.79 ± 0.47
M1 3.15 ± 1.42** 1382.3 ± 680.6 3.5 (1.25, 8.0) 9.8 ± 0.7** 0.43 ± 0.30** 43.08 ± 27.12**
M2 1.25 ± 0.62** 1973.9 ± 1084.4** 2.0 (1.25, 5.0) 3.9 ± 0.6 1.15 ± 0.92** 16.91 ± 10.18
M3 0.39 ± 0.26* 366.3 ± 250.0 3.0 (1.25, 5.0) 5.6 ± 1.3 4.43 ± 5.00* 5.82 ± 6.28
M4 0.03 ± 0.02** 35.4 ± 15.7** 1.9 (0.75, 4.0) 4.7 ± 1.5 51.54 ± 31.52** 0.01 ± 0.01**†
M5 0.04 ± 0.01** 99.9 ± 51.7** 1.5 (0.75, 4.0) 2.7 ± 0.5 29.85 ± 11.98** 0.05 ± 0.05**‡
Geometric mean
ratios (90% CI)
QHS 0.64 (0.56, 0.73)** 0.73 (0.56, 0.94) N.A. 0.92 (0.78, 1.09) 1.69 (1.48, 1.94)** N.A.
DeoxyQHS 0.68 (0.58, 0.79)** 0.78 (0.69, 0.89)* N.A. 0.89 (0.79, 0.99) 1.68 (1.45, 1.95)** 1.18 (0.97, 1.43)
M1 0.85 (0.79, 0.91)** 0.90 (0.80, 1.03) N.A. 0.84 (0.81, 0.88)** 1.18 (1.10, 1.26)** 1.50 (1.31, 1.71)**
M2 0.75 (0.68, 0.83)** 0.83 (0.73, 0.95)** N.A. 0.98 (0.89, 1.07) 1.43 (1.30, 1.58)** 1.34 (1.18, 1.53)
M3 0.79 (0.44, 1.40)* 0.82 (0.70, 0.96) N.A. 0.96 (0.89, 1.04) 0.59 (0.33, 1.05)* 1.53 (1.13, 2.07)
M4 1.66 (1.30, 2.12)** 1.55 (1.26, 1.91)** N.A. 1.07 (0.91, 1.26) 0.38 (0.30, 0.49)** 1.45 (1.13, 1.88)**†
M5 1.98 (1.62, 2.41)** 1.70 (1.41, 2.05)** N.A. 1.12 (0.98, 1.29) 0.36 (0.30, 0.44)** 2.95 (2.43, 3.58)**‡
**: P < 0.01; *: P < 0.05 (single dose compared with multiple dose); †: AUCM4/AUCM1; ‡:AUCM5/AUCM2; N.A., not acquired.
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later than that of QHS (0.8-3.0 hours) and deoxy-QHS
(1.3-4.0 hours). The second dose of QHS-PQ only resulted
in a minor decrease (14.5%) in AUC0-t of M1 (P < 0.01).
The metabolic capability, calculated by AUCM1/AUCQHS,
increased 1.8-fold (1.4-2.3) in eight subjects and kept un-
changed in four subjects (Figure 4).
Monohydroxylated QHS (M2) was observed in relatively
high level (mean Cmax of 2.4 μM). The repeated dose of
QHS led to a significant (P < 0.01) decrease by 25.0-51.5%
in AUC0-t of M2 in nine subjects. The ratio of AUCM2/
AUCQHS increased 1.6-fold (1.2-2.0) in seven subjects and
kept unchanged in five subjects (Figure 4).
The metabolite dihydroxylated QHS (M3) was proposed
to be 9,10-dihydroxyQHS based on a previous report [5].
The AUC0-t of M3 decreased significantly (P < 0.01) in
seven subjects after the repeated dose, whereas the ratio
of AUCM3/AUCQHS increased 1.9-fold (1.5-2.5) in seven
subjects and decreased in four subjects (Figure 4).
Compared with one-day oral dosing of QHS-PQ, the
higher AUC ratio [1.5-fold (90% CI, 1.3-1.7)] of total
phase I metabolites to QHS was observed after two-day
oral doses (P < 0.01).Pharmacokinetics of phase II metabolites of QHS
After QHS-PQ was administrated to healthy Chinese,
two major phase II metabolites (M4 and M5) of QHS
were detected (Figure 2), and they were supposed to be
the glucuronidation products of monohydroxylated
deoxy-QHS (M1) and monohydroxylated QHS (M2),
respectively. The AUC ratios of M4 to M1 and M5 to
M2 were used to evaluate the potential induction of
phase II metabolism. Their mean plasma concentration-
time profiles are shown in Figure 5. The pharmacokinetic
parameters are presented in Table 1.
Time-dependent pharmacokinetics was also observed
for these phase II metabolites after a two-day oral dose
of QHS-PQ. Higher AUC0-t and Cmax values were found
for both M4 (except one subject) and M5 after multiple
oral doses. The dose-normalized AUC0-t increased 1.7-
fold for M4, and the metabolic capability (AUCM4/
AUCM1) increased 2.9-fold (1.5-4.5) in 13 subjects after
the repeated dosing (Figure 6). Similarly, the dose-
normalized AUC0-t increased 2.0-fold (90% CI, 1.6-2.4)
for M5, and the metabolic capability (AUCM5/AUCM2)
increased 3.0-fold (90% CI, 2.4-3.6) after two days’ oral






















































Figure 4 Individual values for AUC ratio of phase I metabolites (M1-M3 and deoxy-QHS) of artemisinin (QHS) to the parent drug in
healthy Chinese (n = 14 each) following one-day or two-day oral doses of QHS (1.8 mg/kg).
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decreased significantly (P < 0.01) after the second dose.
Their Tmax and MRT did not change significantly (P >
0.05) after repeated drug dosing.
The effect of QHS-PQ on the enzyme activity
After an oral administration of two probe drugs (BUP
and MDZ), the dose-normalized AUCs of BUP (0.35 ±
0.23 h⋅kg/L), OH-BUP (3.98 ± 1.45 h⋅kg/L), MDZ
(1.0 ± 0.3 h⋅kg/L) and its metabolite OH-MDZ (0.32 ±
0.09 h⋅kg/L) were obtained. The metabolic capability
was 13.4 ± 5.2 for CYP2B6 (AUC ratio of OH-BUP to
BUP) and 0.34 ± 0.09 for CYP3A4 (AUC ratio of
OH-MDZ to MDZ). The enzyme activity of CYP2B6
(bupropion hydroxylation) and CYP3A (midazolam
hydroxylation) increased 2.1-fold (90% CI, 1.8-2.3) and
3.2-fold (90% CI, 2.8-3.7), respectively, after two days’
oral intake of QHS-PQ compared with day −14. The
induction of CYPs activity by QHS-PQ is summarized
in Table 2.Discussion
For LC-MS technique, quantitation is only possible by
comparison with a standard for each compound. Abso-
lute quantification of metabolites M1-M5 could not be
achieved in this case due to unavailability of reference
substances. Semi-quantitative data can be extracted, for
example, by comparing the integration of the peaks,
from each metabolite to the area of the parent com-
pound. The accuracy of these data, however, relies on
the assumption that the response factor for each metab-
olite is comparable to the response factor for the parent
compound. Because of ion suppression caused by matrix ef-
fects, mobile phase composition, MS detector dynamic
range and modification of the structure during metabolism
response factors of MS will inevitably vary between each
analyte; thus, semi-quantitative data can only be viewed as
a general indication of relative abundance. In this study,
even though no synthetic standard was available for me-
tabolites M1-M5, based on past experience it is reasonable
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Figure 5 Mean (+SD) plasma concentration-time profiles of phase II metabolites of artemisinin (QHS) (the glucuronide of monohydroxylated
deoxy-QHS: M4; the glucuronide of monohydroxylated QHS: M5) in healthy Chinese (n = 14 each) following two consecutive days of oral
doses of QHS (1.8 mg/kg).
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http://www.malariajournal.com/content/13/1/214ionization efficiency to the parent molecule QHS in posi-
tive ion mode. Thus, it can be deduced from these data
that these metabolites are likely major circulating metabo-
lites of QHS in healthy Chinese subjects. The pharmacoki-
netic profiles of QHS and its metabolites in humans after
a single oral dose will be used to compare with that after
multiple oral doses, to evaluate the auto-induction metab-
olism. In this case, the response factor for each metabolite
compared with that of QHS was not considered, and
quantitative data of metabolites M1-M5 could be calcu-
lated using the calibration curve of QHS.
Several published studies have evaluated the pharma-
cokinetics of the parent drug QHS in healthy adults andFigure 6 Individual values for AUC ratio of phase II metabolites (M4 a
artemisinin (QHS) in healthy Chinese (n = 14 each) following one-daypatients including children, after oral administration of
QHS either as monotherapy or ACT [3,8-10]. These
findings suggest that PQ should not influence the phar-
macokinetic characteristics of QHS when co-administered
in the proposed fixed oral combination [8]. Quantitative
prediction of P450-mediated DDIs indicated auto-
induction of QHS clearance with the AUCi/AUC ratio de-
creasing to 59% [13]. The extent of the increase in QHS
CL/F has been reported to be 5- to 7-fold after five days’
oral treatment with 500 mg of QHS [10]. The relative bio-
availability after four to seven days was between 0.13 and
0.29. There was also evidence of a more rapid auto-
induction of QHS metabolism (the AUC of QHSnd M5) to their respective hydroxylated metabolites (M1, M2) of
or two-day oral doses of QHS (1.8 mg/kg).




−1) Tmax (h) MRT (h) CL/F (L/h/kg)
BUP 1-day 0.35 ± 0.23 327.86 ± 180.54 2.1 (1.5, 4.0) 6.8 ± 1.9 3.73 ± 1.91
2-day 0.34 ± 0.18 305.93 ± 146.69 2.5 (0.8, 5.0) 6.1 ± 1.7 3.78 ± 2.05
Geometric mean ratios (90% CI) 0.96 (0.83, 1.12) 0.93 (0.77, 1.13) N.A. 0.89 (0.80, 1.00) 1.01 (0.87, 1.17)
OH-BUP 1-day 3.98 ± 1.45** 517.77 ± 162.04** 5.2 (3.0, 11.0) 19.4 ± 1.4 0.29 ± 0.11**
2-day 8.22 ± 3.43** 856.60 ± 245.03** 7.6 (3.0, 24.0) 20.2 ± 1.5 0.14 ± 0.05**
Geometric mean ratios (90% CI) 2.05 (1.83, 2.30)** 1.65 (1.51, 1.82)** N.A. 1.04 (1.00, 1.07) 0.49 (0.43, 0.55)**
MDZ 1-day 1.00 ± 0.33** 206.03 ± 114.68* 1.3 (0.3, 2.0) 4.1 ± 0.7 1.09 ± 0.33**
2-day 1.55 ± 0.42** 305.26 ± 114.80* 0.8 (0.3, 3.0) 4.2 ± 0.7 0.70 ± 0.21**
Geometric mean ratios (90% CI) 1.55 (1.35, 1.78)** 1.48 (1.12, 1.97)* N.A. 1.04 (0.96, 1.14) 0.64 (0.55, 0.73)**
OH-MDZ 1-day 0.32 ± 0.09** 82.32 ± 50.26** 1.1 (0.3, 2.0) 3.7 ± 1.0 3.31 ± 0.84**
2-day 1.60 ± 0.26** 242.64 ± 81.98** 1.5 (0.8, 3.0) 4.2 ± 0.5 0.64 ± 0.11**
Geometric mean ratios (90% CI) 4.99 (4.66, 5.33)** 2.95 (2.44, 3.56)** N.A. 1.14 (1.01, 1.28) 0.19 (0.18, 0.21)**
AUCOH-BUP/AUCBUP 1-day 13.36 ± 5.24** N.A. N.A. N.A. N.A.
2-day 27.33 ± 10.06** N.A. N.A. N.A. N.A.
Geometric mean ratios (90% CI) 2.05 (1.79, 2.33)** N.A. N.A. N.A. N.A.
AUCOH-MDZ/AUCMDZ 1-day 0.34 ± 0.09** N.A. N.A. N.A. N.A.
2-day 1.10 ± 0.29** N.A. N.A. N.A. N.A.
Geometric mean ratios (90% CI) 3.24 (2.84, 3.69)** N.A. N.A. N.A. N.A.
MDZ: midazolam; BUP: bupropion; OH-MDZ: hydroxymidazolam; OH-BUP: hydroxybupropion.
*: P < 0.05; **: P < 0.01 (1-day compared with 2-day); N.A., not acquired.
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dose [3]. This suggested that the higher clearance of QHS
in children at critical times of malaria could lead to more
failures of ACT than in adults. In this study, the pharma-
cokinetic profiles of QHS metabolites in humans were also
evaluated, which has not been reported.
The dose-normalized AUC value (0.14 ± 0.08 h⋅kg/L)
obtained from a single oral dose of QHS in the present
study was within the range of 0.06-0.31 h⋅kg/L reported
for healthy subjects and patients who received 500 mg
of QHS [8,9], but lower than that in infected children
(0.33-0.49 h⋅kg/L) at the dose of 3.2 mg/kg [3]. The
present results showed that the time-dependent pharma-
cokinetics existed for QHS and its phase I and phase II
metabolites even after a two-day oral dose of QHS-PQ.
Out of expectation, most of phase I metabolites (deoxy-
QHS, M1-M3) showed reduced concentration level,
which was probably caused by the further induction me-
tabolism and/or more rapid subsequent clearance of
those metabolites via phase II glucuronidation. Using
cellular and in vitro CAR-coactivator interaction assays,
deoxy-QHS has been shown to be an agonist of CAR1/3
and PXR, and it demonstrated induction of CYP2B6 and
CYP3A4 expression in primary human hepatocytes [20].
The increased AUC ratio of two phase II metabolites
(M4 and M5) to their respective phase I metabolites
(M1 and M2) gave the direct evidence of auto-inductionof phase II metabolism for QHS. These results also sug-
gested that repeated doses would lead to a lower relative
bioavailability of QHS and potential lower concentration
level of its phase I metabolites. If a third daily dose of
QHS-PQ were to be given, its relative bioavailability
would also be low, especially in children. However, a
three-day QHS-PQ regimen (3.2 and 16.0 mg/kg/day of
QHS and PQ, respectively) has been found to be both
well tolerated and more effective than a two-day regimen
[4], which suggested that the lower bioavailability of the
parent drug QHS and potential lower concentration level
of its phase I metabolites might not be of clinical signifi-
cance in the treatment of malaria infections.
Due to induction of phase I/II metabolism for QHS,
more attention should be paid to the potential effect of
QHS-PQ on the activity of major CYPs and UGTs en-
zymes. CYP2B6 and CYP3A4 have been reported to be
involved in the metabolism of QHS [14,15]. In primary
human hepatocytes, QHS was found to induce the activ-
ity of CYP3A4 and CYP2B6 in primary human hepato-
cytes, whereas QHS was also a weak reversible inhibitor
of CYP2B6 (Ki 4.6 μM) [13]. Previous in vitro studies
implicated that induction of CYP2B6 and CYP3A4 was
the underlying mechanism of the time-dependent
pharmacokinetics of QHS [11-13]. The induction of
CYP3A4 activity by QHS has been evaluated by the ratio
of plasma COH-MDZ to CMDZ at 4 hours [16] or using
Zang et al. Malaria Journal 2014, 13:214 Page 12 of 14
http://www.malariajournal.com/content/13/1/214different probe drugs (omeprazole or cortisol) [17]. The
effect of QHS on the activity of CYP2B6 has been studied
in humans using mephenytoin as a probe. In the present
work, the effect of QHS-PQ on CYP2B6 and CYP3A4 ac-
tivity in healthy Chinese after two consecutive oral doses
of QHS-PQ was investigated. Considering that there is no
report of PQ affecting any of the enzymes studied, the
change of enzyme activity after QHS-PQ pretreatment
was supposed to be the contribution of QHS in the
present study.
In order to obtain metabolic information on different
enzymes in one study, a cocktail approach, which in-
volves the administration of several probe drugs simul-
taneously, is usually applied. By using metabolic ratios
such as the AUC of a metabolite to that of the parent
drug in plasma as metrics, the activity of multiple en-
zymes can be estimated concurrently. A number of stud-
ies have used the cocktail methodology to investigate the
activity of major CYP450 enzymes (CYP1A2, CYP2C19,
CYP2D6, CYP2E1, and CYP3A) [16]. It should be
pointed out that both pharmacokinetic and pharmacody-
namic interactions between cocktail probe drugs should
be taken into consideration. In the present study, it was
of interest to include probes for CYP2B6 and CYP3A4,
as these enzymes have been shown to metabolize QHS
in vitro. BUP and MDZ are well-recognized markers for
evaluation of CYP2B6 and CYP3A activity, respectively,
and have been widely used both in vitro and in vivo. A
cocktail including BUP (100 μM) and MDZ (2 μM) has
been validated in vitro [13,21,22]. To evaluate the activ-
ity of these two enzymes in humans, the pharmacoki-
netic profiles of MDZ and BUP have been evaluated
separately [23-25] or dosed on separate days [26] due to
lack of literature data to support this cocktail.
In the present study, MDZ and BUP were dosed to-
gether as a cocktail, which was validated by comparison
of the present metabolic capability data (AUCmetabolite/
AUCparent drug) with reported results obtained from each
probe alone or validated cocktail drugs. After an oral ad-
ministration of two probe drugs, the dose-normalized
AUC of BUP (0.35 ± 0.23 h kg/L) and its metabolite OH-
BUP (3.98 ± 1.45 h⋅kg/L) corresponded with reported
data obtained in healthy Chinese [24], Korean [25] and
Caucasian volunteers [26]. The metabolic capability of
CYP2B6 was 13.4 ± 5.2, which was in agreement with re-
ported data (6.3-15.3). After an oral dose of this cocktail,
the dose-normalized AUCs of MDZ (1.0 ± 0.3 h⋅kg/L)
and its metabolite OH-MDZ (0.32 ± 0.09 h⋅kg/L) were
similar to the documented data obtained in healthy Chinese
[23] and Caucasian volunteers [25]. The AUC ratio of
OH-MDZ to MDZ was 0.34 ± 0.09, which did not show a
big difference from reported data (0.22-0.30). No serious
drug-related adverse events occurred during and after the
investigation. All volunteers successfully completed thestudy. These results suggested that bupropion (75 mg)
and midazolam (15 mg) could be included in the present
cocktail to evaluate the enzyme activity of CYP2B6 and
CYP3A4, respectively.
The enzyme activity of CYP2B6 (bupropion hydroxyl-
ation) increased 2.1-fold after two days’ oral intake of
QHS-PQ compared with day −14, which suggested that
two days’ regimen of QHS-PQ could induce the activity
of CYP2B6. In a previous population pharmacokinetic
study, the activity of CYP2B6 (S-mephenytoin N-de-
methylation) increased 1.9-fold after multiple adminis-
trations of QHS to CYP2C19-poor metabolizers [12]. It
was found that QHS could induce the activity of CYP2B6
(Emax 1.9-fold and EC50 0.6 μM) in primary human hepa-
tocytes [13]. However, weak inhibition by QHS was also
observed in HLMs. Taking the induction and inhibition
into consideration, quantitative prediction of P450-
mediated DDIs indicated auto-induction of QHS clear-
ance, as a result of a 1.6-fold increase in CYP2B6 activ-
ity. Previous studies provided molecular mechanism of
induction by QHS, which acted as a ligand of human
PXR and CAR. QHS could activate both nuclear receptors
and result in the induction of the expression of CYP2B6,
CYP3A4, and MDR1 in primary human hepatocytes and
in the human intestinal cell line LS174T [27].
MDZ is probably the best available probe to test
CYP3A4 activity, even though it is not selective for
CYP3A4 vs. CYP3A5. In the present study, the CYP3A
activity increased 3.2-fold after two consecutive days of
drug treatment, which indicated that CYP3A4 could be
induced by QHS. After five days’ treatment by QHS,
the plasma COH-MDZ/CMDZ at 4 h (CYP3A activity) has
been found to increase 2.66-fold in healthy subjects
[16], and the increased CYP3A activity (1.6-fold) was
observed even after one single dose. The increased ac-
tivity of CYP3A4 (Emax 3.5-fold and EC50 5.9 μM) by
QHS pretreatment was also observed in primary hu-
man hepatocytes [13]. However, another study showed
CYP3A4-enzymatic activity (omeprazole and cortisol
as probes) was not induced by QHS in humans [17].
The choice of in vivo probe substrates may lead to vari-
able results. In addition, the discrepancy of CYP3A4
activity may be caused by the net effect of induction
and inhibition by QHS, which has been observed in hu-
man liver microsomes at very high concentration (IC50s
of ~50 μM) [13]. Quantitative prediction of P450-
mediated DDIs indicated auto-induction of QHS clear-
ance, as a result of a net 1.9-fold increase in CYP3A4. Out
of expectation, increased concentration level was observed
for both MDZ and its metabolite OH-MDZ. The in-
creased AUC ratio of OH-MDZ to MDZ indicated the in-
duction of CYP3A activity by QHS, and the increased
AUC/dose of MDZ (1.6 ± 0.5 fold) was probably caused by
inhibition of intestinal CYP3A4 enzyme.
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has been reported to be mediated by CYP2A6 with a
probable secondary contribution [14], and minor induc-
tion of mRNA expression of CYP2A6 (Emax 11.7-fold
and EC50 4.0 μM) was observed in primary human hepa-
tocytes [13]. Induction of CYP2A6 (7-hydroxycoumarin
and its glucuronide excreted in human urine) was found
after QHS pretreatment for five days in a previous study
[18] but not observed in another study using 7-
hydroxycoumarin as metrics [16]. QHS did not show in-
duction of UDP glucuroninosyltransferases in primary
human hepatocytes, but induction of glucuronidation
(the AUC ratio of 7-hydroxycoumarin glucuronide to 7-
hydroxycoumarin) existed for QHS in healthy subjects [19].
Based on these previous studies, CYP2A6 and UGTs were
not studied in the present work due to their limited contri-
bution to the initial auto-induction metabolism of QHS.
With a potential for induction and inhibition of drug
metabolism by QHS and the recommendation of QHS-
based combination treatment as first-line therapy of fal-
ciparum malaria by WHO, the risk for drug-drug interac-
tions resulting in a potentiated or diminished activity of
other drugs substantially increases. Moreover, it is import-
ant to realize that humans differ from patients with regard
to the health status, and thus some caution should be ap-
plied when extrapolating metabolism data of QHS from
healthy subjects to patients. Further assessment of induc-
tion of CYP (particularly CYP2B6, CYP3A and CYP2A6)
and UGT enzymes involved in the metabolism of QHS, is
required to clarify the entire picture of the pharmacokin-
etics of QHS in patients and other species of humans.
Conclusions
The results gave the direct evidence for the presence of
auto-induction phase I/II metabolism of QHS in healthy
subjects during the two-day oral doses of QHS-PQ (Arte-
quick), a recently marketed ACT combination therapy.
The auto-induction metabolism also existed for phase I
metabolites of QHS. The CYPs (CYP2B6 and CYP3A4)
activity was induced after two consecutive oral doses of
QHS-PQ. From the point of auto-induction metabolism
and potential drug-drug interactions, a two-day oral regi-
men for QHS-PQ seems more reasonable than the alter-
native three-day treatment recommended for other ACT
by WHO. However, other factors (the effect of malaria in-
fection, the low proportion of QHS in QHS-PQ, potential
under-dosing of PQ, and potential drug resistance caused
by not enough QHS) deserve further evaluation of theor-
etically more efficacious three-day QHS-PQ regimen.
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